ASCO 2026: Reqorsa Gene Therapy Identifies Response Biomarkers for Lung Cancer Treatment
Genprex presented data at ASCO 2026 on successful prediction of progression-free survival biomarkers using Reqorsa (quaratusugene ozeplasmid) gene therapy. The therapy, which restores expression of the TUSC2 tumor suppressor gene, demonstrates the ability to predict patient response in non-small cell and small cell lung cancer.
Data from Genprex for 2026 show: clinical successes do not guarantee market capitalization. Shares plummeted from $55 to $0.92, but the scientific strategy continues. Let's analyze this paradox.
The Essence: What Is Really Happening
ASCO 2026 for Genprex is not a moment of scientific breakthrough but a demonstration of biomarker strategy maturity. The company will present clinical data (abstract e15184) showing that TROP2 and PTEN biomarkers can predict progression-free survival (PFS) in patients receiving Reqorsa. This is the first confirmation that it is possible to determine in advance who will benefit from restoring the TUSC2 tumor suppressor gene.
Behind this lies a shift in the business model of cancer gene therapy. Reqorsa uses not a viral vector but lipid nanoparticles, which dramatically reduces production costs. Combined with response prediction via biomarkers, this turns the therapy into a scalable product.
Timeline and Context
The Reqorsa story is a classic example of a small biotech company surviving on scientific strategy rather than market capitalization.
Key Milestones:
- 2010 — Start of collaboration with MD Anderson.
- 2024 — Successful completion of Acclaim-1 Phase 1 trial: no dose-limiting toxicity, one patient maintains partial remission for over 42 months.
- 2025 — FDA grants Acclaim-3 Fast Track status for small cell lung cancer.
- March 18, 2026 — First identification of TROP2 and PTEN as predictive biomarkers.
- April 21, 2026 — New sponsored research agreement with MD Anderson for in-depth biomarker study.
- April 22, 2026 — Announcement of data presentation at ASCO 2026.
Clinical Program:
- Acclaim-1 (NSCLC, EGFR mutations): Reqorsa + Tagrisso (AstraZeneca) for progression on osimertinib.
- Acclaim-3 (SCLC): Reqorsa + Tecentriq (Genentech) as maintenance therapy. One patient achieved unconfirmed partial remission — treatment ongoing for over 18 months.
The company's strategy is a deliberate bet on combination therapy: gene therapy restores apoptosis and modulates immune response.
Who Wins and Who Loses
Winners:
- Patient Genprex investors (NASDAQ: GNPX). Shares trade at $0.87-0.92 with a market cap of about $9 million. ASCO offers a chance for revaluation if biomarker data are convincing. The company holds two Fast Track and one Orphan Drug designation from the FDA.
- MD Anderson Cancer Center. Sponsored research agreements with biotech companies provide a stable source of funding and intellectual property.
- Patients with EGFR-mutant NSCLC after progression. After osimertinib failure, only platinum-based chemotherapy remains. Reqorsa offers an alternative mechanism.
- AstraZeneca and Genentech. If combinations with Reqorsa work, their drugs gain lifecycle extension in new indications.
Losers:
- Developers of competing delivery systems. Genprex's non-viral platform with lipid nanoparticles shows 10-33-fold higher TUSC2 uptake in tumor cells versus normal cells. This is a benchmark for delivery efficiency.
- Proponents of adeno-associated viral vectors (AAV). Reqorsa is the first systemic non-viral gene therapy drug for cancer. If success is confirmed, it will question the need for viral vectors in oncology.
What the Media Isn't Saying
Non-obvious insight: Genprex demonstrates how a small biotech company transforms into a platform company without capitalization. The market valued the company at $9 million, but behind this lies technology with multi-billion dollar market potential. The reason for the gap is time: major catalysts (Phase 2 results, potential FDA approval) lie beyond the horizon of most biotech investors.
Additional untold points:
- Preclinical data paradox: Laboratory studies show Reqorsa is also effective against ALK-EML4-positive lung cancer. This expands the market, but the data were not included in the ASCO abstract — possibly the company is preparing a separate publication.
- Stock story. The drop from $55 to $0.92 over a year is not only market conditions but also dilution from raising funds for clinical trials. Classic situation: science moves forward, shareholders lose. If ASCO data are strong, this gap could close.
- Normal cell protection mechanism. The claim of 10-33-fold higher uptake by tumor cells is critical. It explains why the therapy does not cause systemic toxicity with intravenous administration.
Forecast: Next 30 Days and 90 Days
30 days (through June 9, 2026, including ASCO May 29 – June 2):
- May 29 – June 2: Presentation of abstract e15184 at ASCO 2026 will spark attention to the company. Shares may temporarily rise to $1.50-2.50 on speculative interest if TROP2/PTEN correlation with PFS data are convincing.
- Early June: At least one mid-tier investment bank (likely biotech-focused) will issue an analyst note assessing Reqorsa's potential. Expected target price $2-3 under a positive scenario.
- June 2026: Data publication may attract potential licensing partners in Asia, especially for the ALK-EML4-positive population.
90 days (through August 7, 2026):
- July-August 2026: Genprex will announce interim enrollment results for Phase 2 trials Acclaim-1 and Acclaim-3 with biomarker enrichment. If 25 patients are enrolled, the company will obtain more reliable efficacy statistics.
- August 2026: First wave of patent applications specifically protecting the method of patient stratification by TROP2/PTEN for Reqorsa therapy will be filed.
- If ASCO data are strong: A large pharmaceutical company (AstraZeneca or Genentech as current partners) may initiate talks to expand collaboration or an acquisition option.
- If data are weak: Risk of delisting from NASDAQ due to non-compliance with minimum share price requirements remains.
Fundamental conclusion: ASCO 2026 for Genprex is a moment of truth. The company will present data answering a key oncology question: can we predict who will benefit from gene therapy that restores a lost tumor suppressor? Success transforms Reqorsa from a niche scientific project into a platform for personalized gene therapy. Failure returns the company to reality where a $9 million market cap is a fair assessment of clinical risks. Trading will close — data will remain.
— Editorial Team
